Results 101 to 110 of about 194,150 (247)
Abstract Polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome, affects 10%–13% of women of reproductive age and remains underdiagnosed despite its substantial health burden. The introduction of the new PMOS nomenclature in 2026 reflects a fundamental shift in understanding the condition as a lifelong endocrine ...
Maria Forslund +5 more
wiley +1 more source
The majority of human endometrial and ovarian cancers express receptors for GnRH type I (GnRH-I). Their proliferation is time- and dose-dependently reduced by GnRH-I and its analogs. GnRH-I analogs activate a phosphotyrosine-phosphatase (PTP) and inhibit
Eicke, Nicola +3 more
core +1 more source
Objective: To investigate the reproductive benefits of combining laparoscopic surgery with GnRH-agonist hormonal therapy in treating women with endometriosis.
Kevin D Tjandraprawira, Tono Djuwantono
doaj +1 more source
DT‐mediated ablation eliminated detectable donor‐derived ectopic lesions. However, pelvic adhesions, collagen‐rich fibrosis, α‐SMA‐positive fibrotic remodeling, and functional behavioral alterations persisted. These findings indicate that lesion ablation alone is insufficient to resolve established adhesion‐associated fibrotic remodeling and identify ...
Sohyeon Yun +10 more
wiley +1 more source
Working model of ERβ isoform signaling in human granulosa cells. Upon E2 binding, ERβ1 activates ERE‐dependent transcription and represses AP‐1 activity through Jun/Fos interactions. In contrast, ERβ2, ERβ4, and ERβ5 lack E2 binding and ERE activity but promote AP‐1‐dependent transcription and counteract ERβ1 repression, including after phosphorylation
Clémentine Marie +8 more
wiley +1 more source
Graves' Disease Associated with Goserelin Acetate [PDF]
We describe a case of Graves' disease associated with goserelin acetate. A 47-year-old woman experienced thyrotoxicosis during the administration of goserelin acetate, a gonadotropin-releasing hormone (GnRH) -agonist.
Ueda, Yasuo, Morita, Shigeki
core
Antitumor effect of GnRH agonist in epithelial overian cancer
Objective. The effects of the gonadotropin releasing hormone (GnRH) agonist (D-Trp6) were examined in two human ovarian cancer cell lines and in severe combined immune deficiency (SCID) mice to evaluate its potential as a cytocidal, cytostatic, or ...
Jae Keun Jung +8 more
core +1 more source
A folic acid (FA)‐conjugated 2‐deoxyglucose dendrimer selectively targets FRβ+ macrophages in endometriotic lesions, enabling precise intracellular delivery of niclosamide. This nonhormonal nanomedicine enhances drug solubility, provides controlled intracellular release, suppresses lesion growth, reduces inflammation and pain, and establishes FRβ ...
Anubhav Dhull +11 more
wiley +1 more source
Abstract Objective To compare pain, menstrual flow, and quality of life (QoL) between women undergoing surgery for endometriosis only compared with women with endometriosis and coexisting adenomyosis. Methods A cross‐sectional study, set in two tertiary hospitals, of reproductive‐aged women (18–50 years) with a preoperative imaging diagnosis of ...
Mariana Matzenbacher Brunoro +5 more
wiley +1 more source
To determine whether concentrations of oxidative stress markers of follicular fluid and serum are different in GnRH agonist protocol from GnRH antagonist ...
TÜRKÇÜOĞLU, ILGIN +9 more
core +1 more source

